PubMed:23838176
Annnotations
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-158 | Sentence | denotes | Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. |
T2 | 159-322 | Sentence | denotes | Alzheimer's disease (AD) is characterized by amyloid-β deposition in amyloid plaques, neurofibrillary tangles, inflammation, neuronal loss, and cognitive deficits. |
T3 | 323-418 | Sentence | denotes | Cannabinoids display neuromodulatory and neuroprotective effects and affect memory acquisition. |
T4 | 419-647 | Sentence | denotes | Here, we studied the impact of cannabinoid receptor type 1 (CB1) deficiency on the development of AD pathology by breeding amyloid precursor protein (APP) Swedish mutant mice (APP23), an AD animal model, with CB1-deficient mice. |
T5 | 648-796 | Sentence | denotes | In addition to the lower body weight of APP23/CB1(-/-) mice, most of these mice died at an age before typical AD-associated changes become apparent. |
T6 | 797-983 | Sentence | denotes | The surviving mice showed a reduced amount of APP and its fragments suggesting a regulatory influence of CB1 on APP processing, which was confirmed by modulating CB1 expression in vitro. |
T7 | 984-1090 | Sentence | denotes | Reduced APP levels were accompanied by a reduced plaque load and less inflammation in APP23/CB1(-/-) mice. |
T8 | 1091-1213 | Sentence | denotes | Nevertheless, compared to APP23 mice with an intact CB1, APP23/CB1(-/-) mice showed impaired learning and memory deficits. |
T9 | 1214-1343 | Sentence | denotes | These data argue against a direct correlation of amyloid plaque load with cognitive abilities in this AD mouse model lacking CB1. |
T10 | 1344-1502 | Sentence | denotes | Furthermore, the findings indicate that CB1 deficiency can worsen AD-related cognitive deficits and support a potential role of CB1 as a pharmacologic target. |
T1 | 0-158 | Sentence | denotes | Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. |
T2 | 159-322 | Sentence | denotes | Alzheimer's disease (AD) is characterized by amyloid-β deposition in amyloid plaques, neurofibrillary tangles, inflammation, neuronal loss, and cognitive deficits. |
T3 | 323-418 | Sentence | denotes | Cannabinoids display neuromodulatory and neuroprotective effects and affect memory acquisition. |
T4 | 419-647 | Sentence | denotes | Here, we studied the impact of cannabinoid receptor type 1 (CB1) deficiency on the development of AD pathology by breeding amyloid precursor protein (APP) Swedish mutant mice (APP23), an AD animal model, with CB1-deficient mice. |
T5 | 648-796 | Sentence | denotes | In addition to the lower body weight of APP23/CB1(-/-) mice, most of these mice died at an age before typical AD-associated changes become apparent. |
T6 | 797-983 | Sentence | denotes | The surviving mice showed a reduced amount of APP and its fragments suggesting a regulatory influence of CB1 on APP processing, which was confirmed by modulating CB1 expression in vitro. |
T7 | 984-1090 | Sentence | denotes | Reduced APP levels were accompanied by a reduced plaque load and less inflammation in APP23/CB1(-/-) mice. |
T8 | 1091-1213 | Sentence | denotes | Nevertheless, compared to APP23 mice with an intact CB1, APP23/CB1(-/-) mice showed impaired learning and memory deficits. |
T9 | 1214-1343 | Sentence | denotes | These data argue against a direct correlation of amyloid plaque load with cognitive abilities in this AD mouse model lacking CB1. |
T10 | 1344-1502 | Sentence | denotes | Furthermore, the findings indicate that CB1 deficiency can worsen AD-related cognitive deficits and support a potential role of CB1 as a pharmacologic target. |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 159-178 | HP_0002511 | denotes | Alzheimer's disease |
T2 | 204-211 | HP_0011034 | denotes | amyloid |
T3 | 228-235 | HP_0011034 | denotes | amyloid |
T4 | 245-268 | HP_0002185 | denotes | neurofibrillary tangles |
T5 | 284-297 | HP_0002529 | denotes | neuronal loss |
T6 | 303-321 | HP_0100543 | denotes | cognitive deficits |
T7 | 542-549 | HP_0011034 | denotes | amyloid |
T8 | 1175-1203 | HP_0002354 | denotes | impaired learning and memory |
T9 | 1263-1270 | HP_0011034 | denotes | amyloid |
T10 | 1421-1439 | HP_0100543 | denotes | cognitive deficits |
DisGeNET
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T0 | 0-22 | gene:1268 | denotes | Cannabinoid receptor 1 |
T1 | 92-112 | disease:C0338656 | denotes | cognitive impairment |
R1 | T0 | T1 | associated_with | Cannabinoid receptor 1,cognitive impairment |
Allie
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
SS1_23838176_1_0 | 159-178 | expanded | denotes | Alzheimer's disease |
SS2_23838176_1_0 | 180-182 | abbr | denotes | AD |
SS1_23838176_3_0 | 450-477 | expanded | denotes | cannabinoid receptor type 1 |
SS2_23838176_3_0 | 479-482 | abbr | denotes | CB1 |
SS1_23838176_3_1 | 542-567 | expanded | denotes | amyloid precursor protein |
SS2_23838176_3_1 | 569-572 | abbr | denotes | APP |
AE1_23838176_1_0 | SS1_23838176_1_0 | SS2_23838176_1_0 | abbreviatedTo | Alzheimer's disease,AD |
AE1_23838176_3_0 | SS1_23838176_3_0 | SS2_23838176_3_0 | abbreviatedTo | cannabinoid receptor type 1,CB1 |
AE1_23838176_3_1 | SS1_23838176_3_1 | SS2_23838176_3_1 | abbreviatedTo | amyloid precursor protein,APP |
DisGeNET5_gene_disease
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
23838176-0#0#22#gene1268 | 0-22 | gene1268 | denotes | Cannabinoid receptor 1 |
23838176-0#54#73#diseaseC0002395 | 54-73 | diseaseC0002395 | denotes | Alzheimer's disease |
23838176-0#92#112#diseaseC0338656 | 92-112 | diseaseC0338656 | denotes | cognitive impairment |
23838176-0#139#146#diseaseC0002726 | 139-146 | diseaseC0002726 | denotes | amyloid |
23838176-3#123#148#gene351 | 542-567 | gene351 | denotes | amyloid precursor protein |
23838176-3#150#153#gene351 | 569-572 | gene351 | denotes | APP |
23838176-3#187#189#diseaseC0002395 | 606-608 | diseaseC0002395 | denotes | AD |
23838176-3#98#100#diseaseC0002395 | 517-519 | diseaseC0002395 | denotes | AD |
23838176-3#187#189#diseaseC0002395 | 606-608 | diseaseC0002395 | denotes | AD |
0#22#gene126854#73#diseaseC0002395 | 23838176-0#0#22#gene1268 | 23838176-0#54#73#diseaseC0002395 | associated_with | Cannabinoid receptor 1,Alzheimer's disease |
0#22#gene126892#112#diseaseC0338656 | 23838176-0#0#22#gene1268 | 23838176-0#92#112#diseaseC0338656 | associated_with | Cannabinoid receptor 1,cognitive impairment |
0#22#gene1268139#146#diseaseC0002726 | 23838176-0#0#22#gene1268 | 23838176-0#139#146#diseaseC0002726 | associated_with | Cannabinoid receptor 1,amyloid |
123#148#gene351187#189#diseaseC0002395 | 23838176-3#123#148#gene351 | 23838176-3#187#189#diseaseC0002395 | associated_with | amyloid precursor protein,AD |
123#148#gene35198#100#diseaseC0002395 | 23838176-3#123#148#gene351 | 23838176-3#98#100#diseaseC0002395 | associated_with | amyloid precursor protein,AD |
123#148#gene351187#189#diseaseC0002395 | 23838176-3#123#148#gene351 | 23838176-3#187#189#diseaseC0002395 | associated_with | amyloid precursor protein,AD |
150#153#gene351187#189#diseaseC0002395 | 23838176-3#150#153#gene351 | 23838176-3#187#189#diseaseC0002395 | associated_with | APP,AD |
150#153#gene35198#100#diseaseC0002395 | 23838176-3#150#153#gene351 | 23838176-3#98#100#diseaseC0002395 | associated_with | APP,AD |
150#153#gene351187#189#diseaseC0002395 | 23838176-3#150#153#gene351 | 23838176-3#187#189#diseaseC0002395 | associated_with | APP,AD |